Literature DB >> 22386481

Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design.

Jaap Verweij1, Maja de Jonge, Ferry Eskens, Stefan Sleijfer.   

Abstract

With the event of new Molecular targets, clinical trial design requirements to perform these trials are changing. This paper discusses some of the considerations that need to be taken into account when designing a trial, including those trials that assess combinations of targets.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Mesh：

Substances：

Year:  2012        PMID： 22386481      PMCID： PMC5528372          DOI： 10.1016/j.molonc.2012.01.009

Source DB:  PubMed          Journal:  Mol Oncol        ISSN： 1574-7891            Impact factor:   6.603


  43 in total

Review 1.  Development of target-based antineoplastic agents.

Authors:  W M Stadler; M J Ratain
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 3.  Accelerated approval of oncology products: the food and drug administration experience.

Authors:  John R Johnson; Yang-Min Ning; Ann Farrell; Robert Justice; Patricia Keegan; Richard Pazdur
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

4.  Early accelerated approval for highly targeted cancer drugs.

Authors:  Bruce A Chabner
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

5.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

6.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

7.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

8.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

9.  Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.

Authors:  O Soepenberg; A Sparreboom; M J A de Jonge; A S Th Planting; G de Heus; W J Loos; C M Hartman; C Bowden; J Verweij
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

10.  Cancer clinical trial outcomes: any progress in tumour-size assessment?

Authors:  Jaap Verweij; Patrick Therasse; Elizabeth Eisenhauer
Journal:  Eur J Cancer       Date:  2008-12-08       Impact factor: 9.162
View more
  8 in total

1.  Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.

Authors:  Dong-Joon Min; Yingdong Zhao; Anne Monks; Alida Palmisano; Curtis Hose; Beverly A Teicher; James H Doroshow; Richard M Simon
Journal:  Cancer Chemother Pharmacol       Date:  2019-07-31       Impact factor: 3.333

2.  A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.

Authors:  Joseph M Ryan; Payal Mittal; Antoine Menoret; Julia Svedova; Jeffrey S Wasser; Adam J Adler; Anthony T Vella
Journal:  Cancer Immunol Immunother       Date:  2018-01-11       Impact factor: 6.968

Review 3.  Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

Authors:  Subramanian Venkatesan; Martine L M Lamfers; Clemens M F Dirven; Sieger Leenstra
Journal:  CNS Oncol       Date:  2016-03-17

Review 4.  The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.

Authors:  Monica Arnedos; Fabrice André; Françoise Farace; Ludovic Lacroix; Benjamin Besse; Caroline Robert; Jean Charles Soria; Alexander M M Eggermont
Journal:  Mol Oncol       Date:  2012-03-16       Impact factor: 6.603

5.  Guidelines for clinical evaluation of anti-cancer drugs.

Authors:  Hironobu Minami; Naomi Kiyota; Shiro Kimbara; Yuichi Ando; Tomoya Shimokata; Atsushi Ohtsu; Nozomu Fuse; Yasutoshi Kuboki; Toshio Shimizu; Noboru Yamamoto; Kazuto Nishio; Yutaka Kawakami; Shin-Ichi Nihira; Kazuhiro Sase; Takahiro Nonaka; Hideaki Takahashi; Yukiko Komori; Koshin Kiyohara
Journal:  Cancer Sci       Date:  2021-06-08       Impact factor: 6.716

6.  Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.

Authors:  Zhonghai Guan; Huanrong Lan; Xiangheng Chen; Xiaoxia Jiang; Xuanwei Wang; Ketao Jin
Journal:  Mol Med Rep       Date:  2017-08-10       Impact factor: 2.952

7.  A potential novel therapy for FGFR1-amplified pancreatic cancer with bone metastasis, screened by next-generation sequencing and a patient-derived xenograft model.

Authors:  Zhonghai Guan; Huanrong Lan; Dan Sun; Xuanwei Wang; Ketao Jin
Journal:  Oncol Lett       Date:  2018-12-28       Impact factor: 2.967

8.  Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.

Authors:  Norihiro Kotani; Arisa Yamaguchi; Tomoko Ohnishi; Ryusuke Kuwahara; Takanari Nakano; Yuka Nakano; Yui Ida; Takayuki Murakoshi; Koichi Honke
Journal:  Cancer Sci       Date:  2019-07-23       Impact factor: 6.716
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.